¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"like this"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • insulin like activity =ILa
    Àν¶¸°¾çȰ¼º(ÀÛ¿ë).
  • insulin-like activity substance
    Àν¶¸°¾çȰ¼º¹°Áú.
  • insulin-like growth factor
    Àν¶¸°À¯»ç¼ºÀåÀÎÀÚ
  • lichen planus-like keratosis
    ÆíÆòż±¾ç °¢È­Áõ
  • lupus erythematosus like syndrome
    È«¹Ý¼º ·çǪ½º¾çÁõÈıº(ûõÚèàõ¡­åÆñøý¦ÏØ )
  • lupus-like anticoagulant
    ·çǪ½º¾ç Ç×ÀÀ°íÀÎÀÚ
  • lupus-like syndrome
    ·çǪ½º¾ç ÁõÈıº
  • map like skull
    Áöµµ»óµÎ°³(ò¢ÓñßÒÔéËÏ).
  • mask like face
    °¡¸é¸ð¾çÀÇ ¾ó±¼.
  • morphea-like basal cell carcinoma
    ±¹¼Ò °æÇÇÁõ¾ç ±âÀú¼¼Æ÷¾Ï
  • morphine like drug
    ¸ð¸£ÇÉÀ¯»ç¾à¹°.
  • non-suppressible insulin-like activity
    ºñ¾ïÁ¦Àν¶¸°¾ç Ȱ¼º
  • norwalk-like virus
    ³ë¸£¿öÅ© (Norwalk) ¸ð¾ç ¹ÙÀÌ·¯½º(¡­Ù¼åÆ ¡­)
  • organic schizophrenia-like disorder
    ±âÁú¼º Á¤½ÅºÐ¿­À¯»çÀå¾Ö(º´)
  • organism, pleuropneumonia-like (PPLO)
    Æó´Á¸·¿°À¯»ç º´¿øÃ¼, PPLO, ¹ÌÄÚÇö󽺸¶
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ACTH-LI adrenocorticotropin-like immunoreactivity
ALLO atypical Legionella-like organism
ALPPL alkaline phosphatase-like, placental
ALS acute lateral sclerosis; advanced life support; afferent loop syndrome; amyotrophic lateral sclerosi...
ALSD Alzheimer-like senile dementia
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
APLP amyloid precursor-like protein
APLP2 Amyloid precursor-like protein 2
beta-END-LI Beta-endorphin-like immunoreactivity
B-l.i. Bombesin-like immunoreactivity
BLP Bombesin-like peptides
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lupus erythematosus like syndrome
    È«¹Ý¼º ·çǪ½º¾ç ÁõÈıº
  • lupus-like syndrome
    ³¶Ã¢ ¾ç»óÀÇ ÁõÈıº
  • mask-like face
    °¡¸é»ó ¾È¸é
  • morphea-like type
    ¹Ý»ó °æÇÇÁõ °°Àº ÇüÅÂ
  • morphine like drug
    ¸ð¸£ÇÉ À¯»ç ¾à¹°
  • needle-like shape
    ħÇü
  • pertussis-like syndrome
    ¹éÀÏÇØ¾ç ÁõÈıº
    ÀÓ»óÀûÀ¸·Î ¹éÀÏÇØ¿Í ±¸º°ÀÌ µÇÁö ¾Ê´Â ÁõÈıºÀ¸·Î¼­, Bordetella
  • petechia-like lesion
    Á¡»ó ÃâÇ÷ °°Àº º´¼Ò
  • pillar-like
    ±âµÕ ¸ð¾çÀÇ
  • plaque like
    ¹ÝÁ¡ °°Àº
  • plaque like lesion
    ¹ÝÁ¡ °°Àº º´¼Ò
  • plaque-like
    ¹ÝÁ¡Çü, ¹ÝÇü
  • plate like atelectasis
    ÆòÆÇ¾ç ¹«±â Æó, ÆÇ¾ç ¹«±â Æó
  • pseudopod-like outgrowth
    À§Á· °°Àº µ¹Ãâ
    °¡Â¥ ´Ù¸®°°ÀÌ Æ¢¾î³ª¿Â µ¹Ãâ¹°.
  • pyoderma granulosum-like ulcer
    ±«Àú¼º ³óÇǼº ±Ë¾ç
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
rosacea-like tuberculid Papular lesions in rosacea, characterised microscopically by perifollicular granulomas with central necrosis and scattered giant cells. Lupus miliaris disseminatus faciei is probably a form of granulomatous rosacea.
Synonym: rosacea-like tuberculid, tuberculoid rosacea.
(05 Mar 2000)
pleuropneumonia like organism Very tinymicroorganisms (usually spherical with a diameter of 0.3 to 0.8 micrometres, the smallest cells known) which are able to slip through most filters andare therefore often found as contaminating organisms in cultures, vaccines and other supposedly sterile preparations. Some types of mycoplasmas cause pneumonia. Mycoplasmal contamination is an important problem in biotechnology, but fortunately the microbes can usually be killed with antibiotics.
(09 Oct 1997)
pleuropneumonia-like organisms The original name given to a group of bacteria which did not possess cell walls; these organism's, isolated from man and other animals, soil, and sewage, are now assigned to the order Mycoplasmatales.
(05 Mar 2000)
corticotropin-like intermediate-lobe peptide <protein> A product of propiomelanocortin with unknown function.
Acronym: CLIP
(05 Mar 2000)
Csk-like protein-tyrosine kinase <enzyme> Phosphorylates c-terminal conserved tyr of src family members; from mouse brain; has 52% identity with mouse csk; mw 52 kD; genbank u05210
Registry number: EC 2.7.1.-
Synonym: ctk (kinase), ctk gene product, csk-type protein-tyrosine kinase, ntk (kinase), bhk (kinase)
(26 Jun 1999)
cyanobacterium-like bodies A Cryptosporidium-like genus of coccidian parasites reported from millipedes, reptiles, insectivores, and a rodent species. Cyclospora is characterised by acid-fast oocysts with two sporocysts, each with two sporozoites. Cyclospora species is an undescribed but distinct species of Cyclospora that is implicated as the cause of a widespread, prolonged but self-limited human diarrhoea in patients in North, Central, and South America; Caribbean countries; Southeast Asia; and eastern Europe previously reported as caused by cyanobacterium-like bodies.
Synonym: cyanobacterium-like bodies.
(05 Mar 2000)
hepatitis c-like viruses A genus of flaviviridae causing parenterally-transmitted non-a, non-b hepatitis (hepatitis c) which is associated with transfusions and drug abuse. Hepatitis c virus is the type species.
(12 Dec 1998)
Shiga like toxin <protein> Group of structurally related toxins that block eukaryotic protein synthesis by cleaving the 28S rRNA subunit of ribosomes.
Examples: Shiga toxin, Shiga like toxins SLT 1 and SLT 2 of Escherichia coli.
(18 Nov 1997)
SLE-like syndrome <syndrome> A disease with manifestations suggestive of systemic lupus erythematosus, without meeting diagnostic criteria for that disease; sometimes used for drug-induced lupus.
(05 Mar 2000)
neoplastic endocrine-like syndromes Endocrine syndromes due to hormone production by neoplasms of non-endocrine tissue, or by other than the usual endocrine tissues. They are often the first indication of a previously undetected neoplasm.
(12 Dec 1998)
nonsuppressible insulin-like activity A blood protein (nsila) which mimics the biological activity of insulin in serum, but is not suppressed by insulin antibodies. During acid-ethanol extraction of cohn fraction III, 10% of the activity is found in the supernatant (nsila-s) and the remaining activity in the precipitate (nsila-p). The latter is a large molecular compound, much less stable than the soluble fraction. Nsila-s is a more potent growth factor than insulin and exhibits sulfation activity.
(12 Dec 1998)
insulin-like activity A measure of substances, usually in plasma, that exert biologic effects similar to those of insulin in various bioassays; sometimes used as a measure of plasma insulin concentrations; always gives higher values than immunochemical techniques for the measurement of insulin.
(05 Mar 2000)
insulin like growth factor <growth factor> Insulin like growth factors I and II are polypeptides with considerable sequence similarity to insulin.
They are capable of eliciting the same biological responses, including mitogenesis in cell culture. On the cell surface, there are two types of insulin like growth factor receptor, one of which closely resembles the insulin receptor (which is also present).
Insulin like growth factor I = somatomedin A = somatomedin C
Insulin like growth factor II = MSA (Multiplication stimulating activity).
Insulin like growth factor 1 is released from the liver in response to growth hormone.
Acronym: IGF
(18 Nov 1997)
insulin-like growth-factor binding protein 1 One of the six homologous proteins that specifically bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions. The function of this protein is not completely defined. However, several studies demonstrate that it inhibits igf binding to cell surface receptors and thereby inhibits igf-mediated mitogenic and cell metabolic actions. (proc soc exp biol med 1993;204(1):4-29)
(12 Dec 1998)
insulin-like growth factor-binding protein 2 One of the six homologous soluble proteins that bind insulin-like growth factors (somatomedins) and modulate their mitogenic and metabolic actions at the cellular level.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á